Clinical Trial Update: Expanded Access to TAK-881 for Children and Teenagers With Primary Immunodeficiency Diseases in the USA

View source ↗

Summary

Expanded access for TAK-881 in pediatric patients with primary immunodeficiency diseases in the USA is now available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunodeficiency Diseases

Drugs mentioned

• TAK-881

Snippet

Sponsor: Takeda | Conditions: Primary Immunodeficiency Diseases (PIDD) | Status: AVAILABLE